Dyadic International Inc Asset Resilience Ratio
Dyadic International Inc asset resilience ratio. Dyadic International Inc (DYAI) has an Asset Resilience Ratio of 26.55% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See DYAI defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Dyadic International Inc (2005–2024)
Asset resilience ratio of Dyadic International Inc from 2005 to 2024. This chart shows how Dyadic International Inc's Asset Resilience Ratio has changed over time. Read debt load of Dyadic International Inc for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Dyadic International Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Dyadic International Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $3.10 Million | 26.55% |
| Total Liquid Assets | $3.10 Million | 26.55% |
Asset Resilience Insights
- Very High Liquidity: Dyadic International Inc maintains exceptional liquid asset reserves at 26.55% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Dyadic International Inc Industry Peers by Asset Resilience Ratio
Compare Dyadic International Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Dyadic International Inc Asset Resilience Ratio by Year (2005–2024)
Dyadic International Inc asset resilience ratio by year from 2005 to 2024. The table below shows the annual Asset Resilience Ratio data for Dyadic International Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 27.76% | $2.76 Million | $9.93 Million | +18.66pp |
| 2023-12-31 | 9.10% | $748.29K | $8.22 Million | -40.83pp |
| 2022-12-31 | 49.93% | $6.85 Million | $13.71 Million | +28.75pp |
| 2021-12-31 | 21.18% | $4.51 Million | $21.30 Million | -6.94pp |
| 2020-12-31 | 28.12% | $8.46 Million | $30.07 Million | -50.37pp |
| 2019-12-31 | 78.50% | $29.40 Million | $37.45 Million | -11.15pp |
| 2018-12-31 | 89.64% | $38.82 Million | $43.30 Million | +7.08pp |
| 2017-12-31 | 82.57% | $41.90 Million | $50.74 Million | +10.93pp |
| 2016-12-31 | 71.64% | $42.05 Million | $58.70 Million | +70.21pp |
| 2014-12-31 | 1.43% | $122.00K | $8.54 Million | +0.09pp |
| 2013-12-31 | 1.34% | $200.00K | $14.94 Million | -0.15pp |
| 2012-12-31 | 1.49% | $192.00K | $12.88 Million | -0.59pp |
| 2011-12-31 | 2.08% | $214.00K | $10.30 Million | -0.34pp |
| 2010-12-31 | 2.41% | $247.00K | $10.23 Million | +0.21pp |
| 2009-12-31 | 2.20% | $316.00K | $14.36 Million | -1.10pp |
| 2008-12-31 | 3.30% | $344.00K | $10.43 Million | +1.96pp |
| 2007-12-31 | 1.34% | $349.00K | $26.09 Million | +1.19pp |
| 2005-12-31 | 0.15% | $35.00K | $23.75 Million | -- |
About Dyadic International Inc
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells industrial enzymes and other proteins in the United States and internationally. It utilizes the C1 platform in pharmaceutical applications, including the development and production of pharmaceutical products. The company offers Dapibus, a protein production platform that enable the rapid development and la… Read more